Clinical Trials Logo
  1. Home
  2. Obsessive-Compulsive Disorder
  3. NCT06466447
  4. Details
NCT06466447 Clinical Trial

Child and Adolescent OCD Outcomes From Exposure and Response Prevention Video Teletherapy Treatment

Obsessive-Compulsive Disorder Clinical Trial

Official title:
Effectiveness of Video Teletherapy in Treating Child and Adolescent Obsessive-Compulsive Disorder With Exposure and Response Prevention: a Retrospective Longitudinal Observational Study

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT06466447
Other study ID # NOCD002
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 23, 2020
Est. completion date May 3, 2024

Study information
Verified date June 2024
Source NOCD
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a naturalistic, observational study of children and adolescents with obsessive-compulsive disorder who were treated with exposure and response prevention via video teletherapy.

Recruitment information / eligibility
Status Completed
Enrollment 2173
Est. completion date May 3, 2024
Est. primary completion date May 3, 2024
Accepts healthy volunteers No
Gender All
Age group 4 Years to 17 Years
Eligibility Inclusion Criteria: - obsessive-compulsive disorder Exclusion Criteria: - none

Study Design

Related Conditions & MeSH terms

Intervention

Behavioral:
• Exposure and response prevention therapy
Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by therapists remotely via video. The treatment was augmented by between-session text messaging.

Locations
Country Name City State
United States NOCD, Inc. Chicago Illinois

Sponsors (1)
Lead Sponsor Collaborator
NOCD

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Dimensional Obsessive-Compulsive Scale self-rated psychometric instrument to measure symptom severity of multiple OCD subtypes change from pre-treatment to post-treatment (after 11 weeks)
Secondary Depression Anxiety and Stress Scale (DASS-21) self-rated psychometric instrument to measure depression, anxiety, and stress pre-treatment, after 4 weeks, and post-treatment (after 11 weeks)
See also
  Status Clinical Trial Phase
Recruiting NCT04934007 - Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder N/A
Recruiting NCT04071990 - Family Involvement in CBGT of OCD: a Randomized Controlled Trial N/A
Completed NCT02541968 - Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Recruiting NCT05391503 - Light Therapy for Obsessive-compulsive Disorder (OCD) N/A
Recruiting NCT04539951 - Pragmatic Trial of Obsessive-compulsive Disorder Phase 2
Completed NCT03416504 - Methods for Managing Intrusive Thoughts N/A
Not yet recruiting NCT06029738 - Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD N/A
Recruiting NCT02844049 - European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS N/A
Completed NCT02911324 - Cannabinoid Medication for Adults With OCD Phase 1/Phase 2
Terminated NCT02909660 - What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder N/A
Terminated NCT02234011 - A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder Phase 2
Completed NCT02217995 - Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients N/A
Withdrawn NCT01953042 - Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders N/A
Completed NCT02655926 - Deep Brain Stimulation for Severe Obsessive Compulsive Disorder N/A
Completed NCT00742664 - Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project Phase 1/Phase 2
Completed NCT04919785 - Deep Brain Stimulation in Severe Obsessive-compulsive Disorder N/A
Terminated NCT00758966 - Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder Phase 2
Completed NCT00523718 - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder Phase 2
Completed NCT00074815 - Treatment of Obsessive Compulsive Disorder in Children Phase 3